Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vortioxetine for Cognitive Dysfunction in Remitted MDD
NCT02279953Phase 3Completed
- Sponsor
- Lundbeck
- Start
- Oct 2014
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of vortioxetine in major depressive disorder (MDD) (3 arms), sponsored by Lundbeck. Primary endpoint: Digit Symbol Substitution Test at 8 weeks. Started Oct 2014; status: completed.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02279953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02279953.